SG10201901825YA - Conjugates comprising cell-binding agents and cytotoxic agents - Google Patents

Conjugates comprising cell-binding agents and cytotoxic agents

Info

Publication number
SG10201901825YA
SG10201901825YA SG10201901825YA SG10201901825YA SG10201901825YA SG 10201901825Y A SG10201901825Y A SG 10201901825YA SG 10201901825Y A SG10201901825Y A SG 10201901825YA SG 10201901825Y A SG10201901825Y A SG 10201901825YA SG 10201901825Y A SG10201901825Y A SG 10201901825YA
Authority
SG
Singapore
Prior art keywords
conjugates
cell
agents
cytotoxic
binding
Prior art date
Application number
SG10201901825YA
Other languages
English (en)
Inventor
Luke B Harris
Daniel Tavares
Lingyun Rui
Nathan Elliott Fishkin
Manami Shizuka
Michael Miller
Ravi V J Chari
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG10201901825YA publication Critical patent/SG10201901825YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201901825YA 2014-09-03 2015-09-02 Conjugates comprising cell-binding agents and cytotoxic agents SG10201901825YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462045264P 2014-09-03 2014-09-03
US201462086986P 2014-12-03 2014-12-03
US201562149379P 2015-04-17 2015-04-17
US201562186235P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
SG10201901825YA true SG10201901825YA (en) 2019-03-28

Family

ID=54147280

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201901825YA SG10201901825YA (en) 2014-09-03 2015-09-02 Conjugates comprising cell-binding agents and cytotoxic agents
SG11201701565PA SG11201701565PA (en) 2014-09-03 2015-09-02 Conjugates comprising cell-binding agents and cytotoxic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701565PA SG11201701565PA (en) 2014-09-03 2015-09-02 Conjugates comprising cell-binding agents and cytotoxic agents

Country Status (13)

Country Link
US (2) US10988531B2 (zh)
EP (1) EP3188733B1 (zh)
JP (1) JP2017529837A (zh)
KR (3) KR102638901B1 (zh)
CN (1) CN107580604A (zh)
AU (1) AU2015312075A1 (zh)
CA (1) CA2957964A1 (zh)
IL (1) IL250711A0 (zh)
MA (1) MA40415A (zh)
RU (1) RU2017110068A (zh)
SG (2) SG10201901825YA (zh)
TW (1) TW201609152A (zh)
WO (1) WO2016036794A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42561A (fr) * 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
PT3189056T (pt) * 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
MA40415A (fr) 2014-09-03 2016-03-10 Immunogen Inc Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
CA2976005A1 (en) 2015-02-06 2016-08-11 Cell Idx, Inc. Antigen-coupled immunoreagents
EP3313884B9 (en) * 2015-06-29 2021-05-19 ImmunoGen, Inc. Anti-cd123 antibodies and conjugates and derivatives thereof
IL305279A (en) 2015-07-21 2023-10-01 Immunogen Inc Methods for the preparation of cytotoxic benzodiazepine compounds
SG11201806142WA (en) * 2016-02-05 2018-08-30 Millennium Pharm Inc Gcc-targeted antibody-drug conjugates
TWI750194B (zh) * 2016-07-05 2021-12-21 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｇｆｒ抗體-藥物偶聯物及其在醫藥上的應用
CN109475639A (zh) 2016-07-22 2019-03-15 尼克塔治疗公司 具有含肟键联的因子viii部分的轭合物
KR20190107656A (ko) * 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
RS63154B1 (sr) * 2016-12-23 2022-05-31 Immunogen Inc Imunokonjugati koji ciljano deluju na adam9 i postupci za njihovu upotrebu
US10792372B2 (en) * 2017-02-28 2020-10-06 Immunogen, Inc. Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
EP3658568A4 (en) * 2017-07-26 2021-04-28 The University of Queensland COMPOUNDS CONTAINING A DISULPHIDE BOND AND ASSOCIATED USES
CA3126646A1 (en) 2017-09-29 2019-04-04 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US20200362054A1 (en) * 2017-11-21 2020-11-19 Brian Granda Trispecific binding molecules against tumor-associated antigents and use thereof
SG11202005541QA (en) * 2018-01-12 2020-07-29 Immunogen Inc Methods for antibody drug conjugation, purification, and formulation
CA3091683A1 (en) 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
JP2021531825A (ja) * 2018-07-09 2021-11-25 マルチチュード インコーポレーテッドMultitude Inc. 葉酸受容体アルファに特異的な抗体
WO2020092631A1 (en) * 2018-10-31 2020-05-07 Fred Hutchinson Cancer Research Center Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
US20210032285A1 (en) * 2019-03-11 2021-02-04 Cell Idx, Inc. Methods, compositions, and kits for trapping modified biomolecules
EP3941503A1 (en) 2019-03-19 2022-01-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
AU2020240310A1 (en) * 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
CN110922482B (zh) * 2019-12-25 2021-08-31 源道隆（苏州）医学科技有限公司 可结合cd19的多肽及其应用
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FR2801904B1 (fr) 1999-12-07 2002-02-08 Pasteur Institut Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn
AU2003299038A1 (en) 2002-09-19 2004-04-08 Centre National De La Recherche Scientifique - Cnrs Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity
RS20050502A (en) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of interferon- beta with enhanced biological potency
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
JP5234734B2 (ja) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド 抗体−薬物結合体および方法
EP1805216A2 (en) 2004-10-18 2007-07-11 Novo Nordisk A/S Growth hormone conjugates
CA2600749C (en) 2005-03-10 2014-04-15 Nascacell Ip Gmbh Dimeric or multimeric microproteins
WO2006115416A2 (en) 2005-04-25 2006-11-02 Ge Healthcare As Liposomes
JP4938263B2 (ja) * 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
JP2009512443A (ja) 2005-10-20 2009-03-26 ザ スクリップス リサーチ インスチチュート 免疫染色及び免疫標的化のためのＦｃ標識化
FR2897616B1 (fr) 2006-02-20 2008-05-30 Univ Grenoble 1 Presentation de motifs de reconnaissance par une matrice multivalente greffee sur un support solide
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
JP2011503000A (ja) * 2007-11-02 2011-01-27 セントコア・オーソ・バイオテツク・インコーポレーテツド 半合成ＧＬＰ−１ペプチド−Ｆｃ融合コンストラクト、その方法及び使用
UA108598C2 (xx) * 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
KR20170085143A (ko) * 2010-02-24 2017-07-21 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US9381058B2 (en) * 2010-11-05 2016-07-05 Ethicon Endo-Surgery, Llc Recharge system for medical devices
ES2717657T3 (es) * 2011-02-15 2019-06-24 Immunogen Inc Métodos para la preparación de conjugados
SG11201407106XA (en) * 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
MX369626B (es) * 2012-05-24 2019-11-13 Mountgate Group Ltd Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
JP6310909B2 (ja) 2012-06-06 2018-04-11 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
WO2014047357A1 (en) 2012-09-21 2014-03-27 The Regents Of The University Of California Modified fc polypeptides, fc conjugates, and methods of use thereof
CN105051923B (zh) * 2013-03-28 2017-12-01 东芝北斗电子株式会社 发光装置及其制造方法
AU2014265659B2 (en) 2013-05-13 2017-03-30 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
HUE055856T2 (hu) * 2013-08-30 2021-12-28 Immunogen Inc Antitestek és vizsgálatok a folsavreceptor 1 kimutatására
CN105764530B (zh) 2013-11-26 2019-09-13 诺华股份有限公司 用于对酮修饰的多肽类进行肟缀合的方法
MA40415A (fr) 2014-09-03 2016-03-10 Immunogen Inc Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques

Also Published As

Publication number Publication date
TW201609152A (zh) 2016-03-16
RU2017110068A3 (zh) 2019-08-26
EP3188733A1 (en) 2017-07-12
JP2017529837A (ja) 2017-10-12
KR102638901B1 (ko) 2024-02-22
CN107580604A (zh) 2018-01-12
US20160095938A1 (en) 2016-04-07
IL250711A0 (en) 2017-08-31
US10988531B2 (en) 2021-04-27
US11732038B2 (en) 2023-08-22
RU2017110068A (ru) 2018-10-03
US20210299271A1 (en) 2021-09-30
SG11201701565PA (en) 2017-03-30
KR102508023B1 (ko) 2023-03-10
CA2957964A1 (en) 2016-03-10
AU2015312075A1 (en) 2017-03-09
KR20230039755A (ko) 2023-03-21
MA40415A (fr) 2016-03-10
EP3188733B1 (en) 2019-11-06
WO2016036794A1 (en) 2016-03-10
KR20240027148A (ko) 2024-02-29
KR20170054430A (ko) 2017-05-17

Similar Documents

Publication Publication Date Title
SG10201901825YA (en) Conjugates comprising cell-binding agents and cytotoxic agents
PH12017500358A1 (en) Cytotoxic benzodiazepine derivatives
TW201613930A (en) Cytotoxic benzodiazepine derivatives
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX346635B (es) Derivados citotoxicos de la benzodiazepina.
MX2023010124A (es) Generacion de acido peroxiformico a traves de formiato de alcohol polihidrico.
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX370807B (es) Anticuerpos que se unen a axl.
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
UA118380C2 (uk) Заміщені сполуки дигідроізохінолінону
PH12016500967A1 (en) Functionalised and substituted indoles as anti-cancer agents
MX354988B (es) Formulaciones de anticuerpo y metodos.
GB201014026D0 (en) Treatment
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134486A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
MX2015004258A (es) Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
SG178967A1 (en) Antimicrobial compositions and products
MX2019005700A (es) Metodos para tratar la osteocondromatosis multiple (mo).
MX2017013669A (es) Composiciones para el tramiento del cancer.
EA201992044A2 (ru) Цитотоксические бензодиазепиновые производные
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy